Clinical trials: Double-blind Randomized Controlled Study
Sjögren´s Disease
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
- Trial name
- THALASSA (NCT07621809)
- Testing
- VAY736
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 570 people
- Sponsor
- Novartis Pharmaceuticals
BK Virus Nephropathy
Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients
This study is being conducted to determine whether MAU868 warrants further clinical development for the prevention of BKV infection in kidney transplant recipients.
- Trial name
- NCT03456999
- Testing
- MAU868
- Sponsor
- Novartis Pharmaceuticals
Shock, Hemorrhagic, Shock, Traumatic
Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients
MP4OX is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia.
- Conditions
- Shock, Hemorrhagic, Shock, Traumatic, Acidosis, Lactic
- Trial name
- NCT01004198
- Testing
- MP4OX, Ringers Lactate solution
- Where
- 13 sites in France, Germany and 2 more
- Volunteers
- 51 people
- Sponsor
- Sangart
Crohn's Disease
Monoclonal Antibody Treatment of Crohn's Disease
This study will examine the safety and effectiveness of an experimental drug called J695 for treating patients with Crohn's disease-a long-term recurring inflammation of the small and large intestine.
- Trial name
- NCT00007163
- Testing
- J695
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy…
- Trial name
- NCT06829563
- Testing
- RZ-629, Fasted, Fed
- Where
- Australia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Rezubio Pharmaceuticals Co., Ltd.
Hypertension
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
- Trial name
- NCT00219063
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 844 people
- Sponsor
- Novartis
Malaria
Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine
Background: Malaria is a disease that is spread by mosquitoes. Researchers are looking for a vaccine that can prevent mosquitoes from transmitting malaria to people.
- Trial name
- NCT01867463
- Testing
- Pfs25-EPA/Alhydrogel, Euvax B, Menactra
- Where
- Mali
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT03789292
- Testing
- CT-P17 SC, Humira SC
- Where
- Bulgaria
- Volunteers
- 648 people
- Sponsor
- Celltrion
Postherpetic Neuralgia, Diabetic Polyneuropathies
Botulinum Toxin in Peripheral Neuropathic Pain
Pain due to peripheral nerve lesion remains extremely difficult to treat and current treatments have onl moderate efficacy and/or side effects.
- Conditions
- Postherpetic Neuralgia, Diabetic Polyneuropathies, Other Polyneuropathies
- Trial name
- NCT01251211
- Testing
- botulinum toxin type A
- Where
- 3 sites in Brazil, France
- Volunteers
- 66 people
- Sponsor
- Hospital Ambroise Paré Paris
Influenza
A Trial of RLX-2508-102 in Healthy Volunteers
The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose and multiple dose of RLX-2508 in healthy participants across different ethnic backgrounds.
- Trial name
- NCT07873671
- Testing
- RLX-2508
- Where
- 3 sites in Australia
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Schizophrenia
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
The purpose of this study is to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (SGA) in participants with stable…
- Trial name
- NCT02079844
- Testing
- Roflumilast, Second generation antipsychotic
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Takeda
Urinary Bladder, Overactive
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
- Trial name
- CAPRICORN (NCT00912964)
- Testing
- Mirabegron
- Where
- 151 sites in United States, Canada and 9 more
- Volunteers
- 2,030 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05995964
- Testing
- PF-07275315, PF-07264660
- Where
- 96 sites in United States, Australia and 5 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Benign Prostatic Hyperplasia
Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.
- Trial name
- NCT00386009
- Testing
- Tadalafil
- Where
- 13 sites in United States, Greece and 1 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis. The main questions it arms to answer are: 1.
- Trial name
- NCT06361199
- Testing
- Proximod
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Longevity Inc.
Neurodevelopmental Disorders
IAMA-6 Oral Dose Study in Healthy Adults
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of IAMA-6 administered orally to healthy adults.
- Trial name
- NCT06300398
- Testing
- IAMA-6
- Where
- Italy
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Iama Therapeutics S.r.l.
Diabetes Type 2
Mineralocorticoid Receptor Antagonists in Type 2 Diabetes
The aim of this study is to investigate the effect of selective blocking of the mineralocorticoid receptor in patients with type 2 diabetes on insulin resistance, lipid metabolism and myocardial function.
- Trial name
- NCT02809963
- Testing
- Eplerenone
- Where
- Denmark
- Volunteers
- 140 people
- Sponsor
- Herlev Hospital
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Gram-negative Bacterial Infection
Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired Gram negative infection.
- Trial name
- NCT01015014
- Testing
- AN3365
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease, Huntington Disease
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and…
- Trial name
- NCT00831506
- Testing
- digoxin, dimebon
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.